Emory University increased its stake in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 31.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,543 shares of the company’s stock after buying an additional 17,469 shares during the period. WAVE Life Sciences makes up about 1.9% of Emory University’s portfolio, making the stock its 18th largest position. Emory University owned approximately 0.31% of WAVE Life Sciences worth $2,022,000 as of its most recent filing with the SEC.
Other hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of WAVE Life Sciences by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 31,350 shares of the company’s stock valued at $862,000 after buying an additional 279 shares during the period. Strs Ohio increased its position in shares of WAVE Life Sciences by 86.7% in the first quarter. Strs Ohio now owns 11,200 shares of the company’s stock valued at $308,000 after buying an additional 5,200 shares during the period. Deschutes Portfolio Strategy LLC increased its position in shares of WAVE Life Sciences by 2.9% in the first quarter. Deschutes Portfolio Strategy LLC now owns 10,628 shares of the company’s stock valued at $292,000 after buying an additional 297 shares during the period. Teachers Advisors LLC increased its position in shares of WAVE Life Sciences by 10.0% in the fourth quarter. Teachers Advisors LLC now owns 13,088 shares of the company’s stock valued at $342,000 after buying an additional 1,190 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of WAVE Life Sciences during the fourth quarter valued at approximately $18,088,000. Institutional investors own 56.84% of the company’s stock.
Shares of WAVE Life Sciences Ltd. (NASDAQ WVE) traded up 7.69% on Friday, hitting $21.00. The stock had a trading volume of 124,724 shares. The firm’s 50-day moving average price is $20.80 and its 200 day moving average price is $26.16. The firm’s market cap is $582.06 million. WAVE Life Sciences Ltd. has a 52-week low of $17.41 and a 52-week high of $40.15.
WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.80 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%. On average, equities research analysts predict that WAVE Life Sciences Ltd. will post ($3.25) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Emory University Has $2.02 Million Stake in WAVE Life Sciences Ltd. (WVE)” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/06/16/wave-life-sciences-ltd-wve-stake-increased-by-emory-university-updated-updated.html.
WVE has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a research report on Monday, March 27th. Jefferies Group LLC reissued a “buy” rating and set a $42.00 price target on shares of WAVE Life Sciences in a research report on Wednesday, April 26th. JMP Securities reaffirmed an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research report on Friday, June 9th. Finally, ValuEngine downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $42.00.
In other WAVE Life Sciences news, Director Masaharu Tanaka sold 433,825 shares of the company’s stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $24.91, for a total transaction of $10,806,580.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 62.25% of the stock is owned by corporate insiders.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.